tofacitinib

A 74-year-old Japanese woman with rapidly progressive DM-associated ILD was treated with high-dose glucocorticoids, intravenous cyclophosphamide, and cyclosporine, followed by tofacitinib due to an insufficient response. Discontinuation of tofacitinib alone resulted in rapid clinical and radiological improvement. This case highlights PAP as a rare, potentially reversible complication during JAK inhibitor therapy in anti-MDA5 antibody-positive DM-associated ILD and underscores the importance of considering PAP when elevated KL-6 levels and radiological abnormalities occur despite only mild respiratory symptoms.

Standard screening practices for LTB, prior to starting advanced therapy, remain suboptimal (< 60%) in India despite high TB endemicity.

P=N/A, N=116, Not yet recruiting, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University

P4, N=20, Not yet recruiting, Dermatology Hospital of Southern Medical University; Dermatology Hospital of Southern Medical University

P4, N=26, Not yet recruiting, Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Provincial Hospital Affiliated to Shandong First Medical Univer

P=N/A, N=60, Recruiting, The First Affiliated Hospital of Army Medical University (Southwest Hospital); The First Affiliated Hospital of Army Medical University (Southwest Hos | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Nov 2025

The effect of RT (8 and 3 × 8 Gy) on Interferon beta (IFNβ), IFN-stimulated genes (ISGs), and HLA-class-I expression in combination with IFN-type-I-response inhibitors (Ruxolitinib, Tofacitinib, Amlexanox) targeting the JAK and TBK1 was studied with Flow cytometry and RT-PCR. The current study supports the theory that baseline autophagy, RT-induced autophagy blockage, and IFN-type-I response enhancement define the HLA-class-I levels in NSCLC cells. This complex interplay emerges as a promising target for the development of radio-vaccination strategies to enhance the efficacy of radio-immunotherapy.

P=N/A, N=10, Recruiting, Pfizer | N=375 --> 10

P=N/A, N=24, Enrolling by invitation, Tongji Hospital | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026

P4, N=10, Not yet recruiting, University of California, San Francisco

P=N/A, N=152, Completed, Pfizer | Recruiting --> Completed | N=280 --> 152

P=N/A, N=186, Not yet recruiting, The Fourth Affiliated Hospital of Zhejiang University School of Medicine